We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
- Authors
Jin, Rui; Li, Jie; Jin, Zhou; Lu, Yuefei; Shao, Yang W.; Li, Wen; Zhao, Guofang; Xia, Yang
- Abstract
The best responses were achieved on gefitinib with a 6-year PFS.[3] On the other hand, the effectiveness of third-generation EGFR-TKI, osimertinib, also appears to be encouraging from pilot study, in which durable response was observed after resistance to first and second-generation EGFR-TKIs.[1] Thus, the underlying mechanism is worthy in-depth investigation. In contrast, comparable binding energy was found for osimertinib, -26.89 ± 4.51 kcal/mol for EGFR-WT and -28.49 ± 4.49 kcal/mol for EGFR-KDD, and small increase was found for afatinib, -37.01 ± 5.62 kcal/mol for EGFR-WT and -30.47 ± 4.71 kcal/mol for EGFR-KDD. Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient Harboring epidermal growth factor receptor tandem kinase domain duplication.
- Subjects
EPIDERMAL growth factor receptors; ERLOTINIB
- Publication
International Journal of Cancer, 2019, Vol 145, Issue 10, p2884
- ISSN
0020-7136
- Publication type
Article
- DOI
10.1002/ijc.32617